Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (211-220 of 320) with videos related to

Pageof 32
Sort By:
BMC Cancer|March 28, 2006
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Ursula Pluschnig, et al.
European Cytokine Network|October 7, 2000
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2G J Locker, J Kofler, B Stoiser, et al.
Annals of Surgical Oncology|November 11, 2010
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility studyG Spizzo, D Öfner, A de Vries, et al.
Clinical Breast Cancer|July 2, 2017
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II StudyGuenther G Steger, Adriana Dominguez, Natalia Dobrovolskaya, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancerCatharina Wenzel, Gottfried J Locker, Ursula Pluschnig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patientsD Kandioler-Eckersberger, C Ludwig, M Rudas, et al.
Breast Cancer Research and Treatment|October 25, 2006
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experienceG G Steger, R Bartsch, C Wenzel, et al.
Cancer Research|July 1, 1997
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patientsM Müller, R M Mader, B Steiner, et al.
Endocrine-Related Cancer|March 26, 2003
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapyS Taucher, M Rudas, M Gnant, et al.
Pageof 32

Showing results (211-220 of 320) with videos related to

Sort By:
Pageof 32
BMC Cancer|March 28, 2006
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Ursula Pluschnig, et al.
European Cytokine Network|October 7, 2000
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2G J Locker, J Kofler, B Stoiser, et al.
Annals of Surgical Oncology|November 11, 2010
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility studyG Spizzo, D Öfner, A de Vries, et al.
Clinical Breast Cancer|July 2, 2017
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II StudyGuenther G Steger, Adriana Dominguez, Natalia Dobrovolskaya, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancerCatharina Wenzel, Gottfried J Locker, Ursula Pluschnig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patientsD Kandioler-Eckersberger, C Ludwig, M Rudas, et al.
Breast Cancer Research and Treatment|October 25, 2006
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experienceG G Steger, R Bartsch, C Wenzel, et al.
Cancer Research|July 1, 1997
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patientsM Müller, R M Mader, B Steiner, et al.
Endocrine-Related Cancer|March 26, 2003
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapyS Taucher, M Rudas, M Gnant, et al.
Pageof 32